A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II/III
Latest Information Update: 01 Nov 2017
At a glance
- Drugs TG 4010 (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms TIME
- Sponsors Transgene
- 30 Oct 2017 According to a Transgene media release, data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) Meeting 2017.
- 04 Jan 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Nov 2016 This trial was discontinued in Germany, according to European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History